[ad_1]
Coronavirus – All news: The United States government has already signed a contract with Regeneron to supply up to 300,000 servings of the “cocktail”
The American pharmaceutical company Regeneron Pharmaceuticals, in which scientists of Greek origin play a leading role at the administrative and research level, announced that Experimental “cocktail” of two monoclonal antibodies developed, reduced levels of coronavirus (viral load) and improvement of symptoms in patients not treated with mild to moderate Covid-19.
“We hope that this data supports urgent authorization from the US Food and Drug Administration (FDA),” said George Gankopoulos, the company’s co-founder, president and chief scientist, according to Reuters. The FDA may grant such authorization under the urgent procedure, before a drug completes the standard test cycle required for normal marketing authorization.
REGN-CoV-2 antibody treatment already It is also being studied in patients with severe Covid-19 who have been admitted to hospitals. (so they have a high viral load), as well as for prevention of infection in people who are frequently exposed to coronavirus carriers. Regeneron did not say when the first results are expected for these other two studies, however, its shares have already risen on the US stock market, as Investors seem to see a positive outlook.
the results of the first study in 275 patients showed that the greatest benefit of treatment are those that do not create high levels of anti-coronavirus antibodies in your body. This means that Regeneron medicine will help more patients whose immune systems are not strong enough to deal with the “invader” with their own “weapons.”
REGN-CoV-2 belongs to the class of antibodies that are developed in the laboratory through biotechnological methods and then mass produced in the factory. Several companies (like Eli Lilly) follow this technique to find antiviral drugs against SARS-CoV-2.
Regeneron tried two different doses of your “cocktail” in two groups of patients: those who had a strong immune response and those who had a weak reaction. In the second group, the median time to remission was 13 days for patients taking placebo, eight days for those taking the high dose, and six days for those taking the low dose.
The company claimed that its medicinal cocktail rapidly reduced virus levels in patients with a weak immune response. Also, those who had the highest viral load levels at the start of the clinical trial had the greatest reductions in viral load after IV treatment.
The US government has already signed a contract with Regeneron to supply up to 300,000 servings of the “cocktail.” The US company has also signed an agreement with the Swiss pharmaceutical company Roche for the production and distribution of the drug in the rest of the world outside the US.
Δeither all the latest news from Greece and the world, as it happens, on Newsbomb.gr
Read also:
Koronovios – Attica near the confinement: The five meters if the cases increase
